Alnylam Pharmaceuticals

NSQ:ALNY · US02043Q1076

BiotechnologyLarge

360

Value39

Profit price13

EV / EBIT20

Price / Owner Earnings5

Cash yield56

Sales & asset price38

Price/Sales62

EV / Gross Profit49

Price/Book3

Quality74

Returns on capital91

Return on Capital86

Cash Return on Capital96

Return on Equity91

Profit margins74

EBIT Margin52

Gross Profitability96

Cash backing64

Cash Conversion62

Accruals69

Owner Earnings Margin60

Growth64

Sales growth66

Profit growth98

Profit Growth98

Long-Term EPS Growth97

Reinvestment65

Price momentum18

Safety53

Debt load12

Debt serviceability88

Refinancing76

Debt Payback100

Liquidity91

Sentiment50

Analyst ratings15

Expectations trend63

Opinion Changes50

Price Target Upside75

Market mood97

Value Creation20/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Alnylam Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeLarge

TypePublic Company

ExchangeNASDAQGS

Founded2003

Employees2,589

Websitealnylam.com

ISINUS02043Q1076

Last UpdateApr 2, 2026

Indices

NASDAQ 100 (USA)NASDAQ (USA)D.J. US Health Care

Themes

DiabetesCardiovascularInfectious DiseasesNeurologyEndocrinologyHematologyNephrologyObesityCentral Nervous SystemGeneticsHepatologyBiotechnologyHealth CareMedicalPharmaceuticalTherapeutics

Description

Alnylam Pharmaceuticals, Inc. (Alnylam), a global commercial-stage biopharmaceutical company, develops novel therapeutics based on ribonucleic acid interference, or RNAi. As of December 31, 2025, the company’s efforts to advance this revolutionary a…

Analysis

Quality compounder

Alnylam Pharmaceuticals, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 73.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 24% a year, against analyst forecasts of 71%. The price, in other words, assumes less than the experts do.

Growth is solid; the safety picture is adequate. The company scores 20/20 on our value-creation score: strong value creator.

Flags to be aware of: Some accounting patterns deserve a closer look. Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Feb 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Alnylam Pharmaceuticals with its peers

BridgeBio Pharma

NSQ:BBIO

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Vir Biotechnology

NSQ:VIR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

MacroGenics

NSQ:MGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Editas Medicine

NSQ:EDIT

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Protagonist Therapeutics

NMQ:PTGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Xenon Pharmaceuticals

NMQ:XENE

CountryCanada

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →